[PDF][PDF] Can personalized neoantigens raise the T cell bar?
N Zaidi - Cell, 2020 - cell.com
N Zaidi
Cell, 2020•cell.comOtt et al. report the results of a phase 1B study in which a personalized neoantigen vaccine
was combined with programmed death receptor-1 blockade in patients with advanced
cancers. The study provides a framework for combinatorial vaccine therapies that could
mount robust T cell responses, enhance tumor killing, and provide clinical benefit.
was combined with programmed death receptor-1 blockade in patients with advanced
cancers. The study provides a framework for combinatorial vaccine therapies that could
mount robust T cell responses, enhance tumor killing, and provide clinical benefit.
Ott et al. report the results of a phase 1B study in which a personalized neoantigen vaccine was combined with programmed death receptor-1 blockade in patients with advanced cancers. The study provides a framework for combinatorial vaccine therapies that could mount robust T cell responses, enhance tumor killing, and provide clinical benefit.
cell.com